5/25/2017 Digoxin ­ DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1) Enzymes (2) Transporters (12) Biointeractions (17) (/drugs/DB00390/biointeractions) Show Drugs with Similar Structures

Get DrugBank to go! The DrugBank app for iOS and Android is coming soon. (http://eepurl.com/bZh6g9)

Sign up to get early access (http://eepurl.com/bZh6g9)

Identication

Name Digoxin

Accession Number DB00390 (APRD00098)

Type Small Molecule

Groups Approved

Description A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone digoxigenin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial brillation and in the management of congestive heart failure with atrial brillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)

Structure

O O

O H CH

CH CH CH

HO HO O O O (/structures/DB00390/image.svg) O H

O HO O HO O

CH

 MOL (/structures/small_molecule_drugs/DB00390.mol) SDF (/structures/small_molecule_drugs/DB00390.sdf) PDB (/structures/small_molecule_drugs/DB00390.pdb)

SMILES (/structures/small_molecule_drugs/DB00390.smiles) InChI (/structures/small_molecule_drugs/DB00390.inchi)

https://www.drugbank.ca/drugs/DB00390 1/25 5/25/2017 Digoxin ­ DrugBank

Synonyms 12beta-Hydroxydigitoxin

12β-hydroxydigitoxin

4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl- oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one

Digazolan

Digossina

Digoxin

Digoxina

Digoxine

Digoxinum

Lanadicor

External IDs  Not Available

Product Not Available Ingredients 

Approved Show 10 entries Prescription Products Search

Name  Dosage  Strength  Route  Labeller  Marketing Start  Marketing End  

Digoxin Tablet .25 mg/1 Oral Par Pharmaceutical 2014-01-14 Not applicable

Digoxin Tablet .125 mg/1 Oral Remedy Repack 2016-09-12 2017-03-04

Digoxin Solution .05 mg/mL Oral Precision Dose, Inc. 2017-01-19 Not applicable

Digoxin Tablet .125 mg/1 Oral Par Pharmaceutical 2014-01-14 Not applicable

Digoxin Tablet .25 mg/1 Oral Remedy Repack 2016-09-21 2017-03-04

Digoxin Tablet .125 mg/1 Oral State of Florida DOH Central Pharmacy 2014-11-01 Not applicable

Digoxin Tablet .125 mg/1 Oral Nucare Pharmaceuticals, Inc. 2014-01-14 Not applicable

Digoxin Tablet .25 mg/1 Oral Remedy Repack 2017-03-09 Not applicable

Digoxin Tablet .125 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 2014-01-14 Not applicable

Digoxin Tablet .25 mg/1 Oral Nucare Pharmaceuticals, Inc. 2014-01-14 Not applicable

Showing 1 to 10 of 57 entries

Previous 1 2 3 4 5 6 Next

https://www.drugbank.ca/drugs/DB00390 2/25 5/25/2017 Digoxin ­ DrugBank

Approved Generic Show 10 entries Prescription Products Search

Name Dosage  Strength  Route  Labeller  Marketing Start  Marketing End  

Apo- Tablet 0.25 mg Oral Apotex Corporation 2006-06-22 Not applicable digoxin

Apo- Tablet 0.125 mg Oral Apotex Corporation 2006-06-22 Not applicable digoxin

Apo- Tablet 0.0625 mg Oral Apotex Corporation 2006-06-22 Not applicable digoxin

Digitek Tablet .125 mg/1 Oral Mylan Institutional 2015-05-06 Not applicable

Digitek Tablet .125 mg/1 Oral Mylan Pharmaceuticals 2014-11-17 Not applicable

Digitek Tablet .25 mg/1 Oral Mylan Institutional 2015-05-06 Not applicable

Digitek Tablet .25 mg/1 Oral Mylan Pharmaceuticals 2014-11-17 Not applicable

Digox Tablet 250 ug/1 Oral Aidarex Pharmaceuticals LLC 2002-07-26 Not applicable

Digox Tablet 125 ug/1 Oral TYA Pharmaceuticals 2002-07-26 Not applicable

Digox Tablet 125 ug/1 Oral Carilion Materials Management 2002-07-26 Not applicable

Showing 1 to 10 of 76 entries

Previous 1 2 3 4 5 … 8 Next

Approved Over the Not Available Counter Products

Unapproved/Other Not Available Products 

https://www.drugbank.ca/drugs/DB00390 3/25 5/25/2017 Digoxin ­ DrugBank

International Show 10 entries Brands Search

Name  Company 

Agoxin Aristopharma

Cardiacin Center

Cardiogoxin Medipharma

Cardioxin Oboi

Cardoxin Not Available

Celoxin Celon

Centoxin Opsonin

Digacin mibe

Digocard-G Klonal

Digoxina GlaxoSmithKline

Showing 1 to 10 of 16 entries

Previous 1 2 Next

Brand mixtures Not Available

Categories Anti-Arrhythmia Agents (/categories/DBCAT000520) Bradycardia-Causing Agents (/categories/DBCAT002703) Carbohydrates (/categories/DBCAT000085) Cardanolides (/categories/DBCAT000822) Cardenolides (/categories/DBCAT000823) Cardiac Glycosides (/categories/DBCAT000821) Cardiac Therapy (/categories/DBCAT002210) Cardiotonic Agents (/categories/DBCAT000589) Cardiovascular Agents (/categories/DBCAT000010) Cardiovascular System (/categories/DBCAT002169) Cytochrome P-450 CYP3A4 Substrates (/categories/DBCAT002646) Digitalis Glycosides (/categories/DBCAT000820) Enzyme Inhibitors (/categories/DBCAT000003) Glycosides (/categories/DBCAT000257) OATP1B1/SLCO1B1 Substrates (/categories/DBCAT002658) P-glycoprotein/ABCB1 Inducers (/categories/DBCAT002666) P-glycoprotein/ABCB1 Inhibitors (/categories/DBCAT002667) P-glycoprotein/ABCB1 Substrates (/categories/DBCAT002668) Protective Agents (/categories/DBCAT000367) Steroids (/categories/DBCAT000309) https://www.drugbank.ca/drugs/DB00390 4/25 5/25/2017 Digoxin ­ DrugBank

UNII 73K4184T59  (http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=73K4184T59)

CAS number 20830-75-5

Weight Average: 780.9385 Monoisotopic: 780.429606756

Chemical Formula C41H64O14

InChI Key LTMHDMANZUZIPE-PUGKRICDSA-N

InChI InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14- 31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1- 5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

IUPAC Name 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4- hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one SMILES [H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O) [C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1

Pharmacology

Indication For the treatment and management of congestive cardiac insufciency, arrhythmias and heart failure.

Structured Chronic Atrial Fibrillation (/indications/DBCOND0065022) Indications  NYHA Class I or II heart failure (/indications/DBCOND0025082) NYHA Class III Heart Failure (/indications/DBCOND0048244)

Pharmacodynamics Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial brillation.

Mechanism of Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX)in turn tries to extrude the sodium action and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

Pharmacological Target Kind action Actions Organism UniProt ID

Sodium/potassium-transporting ATPase subunit alpha- Protein yes Not Human P05023  (http://www.uniprot.org/uniprot/P05023) details 1 Available

Related Articles

Absorption Absorption of digoxin from the elixir pediatric formulation has been demonstrated to be 70% to 85% complete (90% to 100% from the capsules, and 60% to 80% for tablets).

Volume of Not Available distribution

Protein binding 25%

https://www.drugbank.ca/drugs/DB00390 5/25 5/25/2017 Digoxin ­ DrugBank

Metabolism Hepatic (but not dependent upon the cytochrome P-450 system). The end metabolites, which include 3 b-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation.

Substrate Enzymes Product

Digoxin  3 b-digoxigenin (/metabolites/DBMET00697) Details (/reactions/718) Not Available

Digoxin  3-keto-digoxigenin (/metabolites/DBMET00716) Details (/reactions/737) Not Available

Route of Following intravenous administration to healthy volunteers, 50% to 70% of a digoxin dose is excreted unchanged in the urine. elimination

Half life 3.5 to 5 days

Clearance Not Available

Toxicity Toxicity includes ventricular tachycardia or ventricular brillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).

Affected organisms Humans and other mammals

Pathways Not Available

Pharmacogenomic Not Available Effects/ADRs 

Interactions

https://www.drugbank.ca/drugs/DB00390 6/25 5/25/2017 Digoxin ­ DrugBank

Drug Interactions Show 10 entries  Search

Drug  Interaction  Drug group 

1,10-Phenanthroline The serum concentration of Digoxin can be increased when it is combined with 1,10-Phenanthroline. Experimental (/drugs/DB02365)

2-(4-Chlorophenyl)-5- Digoxin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. Experimental Quinoxalinecarboxamide (/drugs/DB03509)

2-Methoxyestradiol Digoxin may decrease the cardiotoxic activities of 2-Methoxyestradiol. Investigational (/drugs/DB02342)

3-Methoxybenzamide Digoxin may decrease the cardiotoxic activities of 3-Methoxybenzamide. Experimental (/drugs/DB03073)

3,4-Dichloroisocoumarin The serum concentration of Digoxin can be increased when it is combined with 3,4- Experimental (/drugs/DB04459) Dichloroisocoumarin.

3,4-Dihydroxybenzoic Acid Digoxin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid. Experimental (/drugs/DB03946)

4-(2- The serum concentration of Digoxin can be increased when it is combined with 4-(2- Experimental AMINOETHYL)BENZENESULFONYL AMINOETHYL)BENZENESULFONYL FLUORIDE. FLUORIDE (/drugs/DB07347)

7-Hydroxystaurosporine Digoxin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine. Experimental (/drugs/DB01933)

8-azaguanine (/drugs/DB01667) Digoxin may decrease the cardiotoxic activities of 8-azaguanine. Experimental

Abiraterone (/drugs/DB05812) Digoxin may decrease the cardiotoxic activities of Abiraterone. Approved

Showing 1 to 10 of 848 entries

Previous 1 2 3 4 5 … 85 Next

Food Interactions Avoid avocado. Avoid bran and high ber foods within 2 hours of taking this medication. Avoid excess salt/sodium unless otherwise instructed by your physician. Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication. Avoid salt substitutes containing potassium. Limit garlic, ginger, gingko, and horse chestnut.

References

Synthesis Wolfgang Voigtlander, Fritz Kaiser, Wolfgang Schaumann, Kurt Stach, “Preparation of C22-alkyl derivative of digoxin.” U.S. Patent US3981862, issued October, 1972. Reference US3981862  (https://www.google.com/?tbm=pts#q=3981862&tbm=pts)

https://www.drugbank.ca/drugs/DB00390 7/25 5/25/2017 Digoxin ­ DrugBank

General References 1. Thompson DF, Carter JR: Drug-induced gynecomastia. Pharmacotherapy. 1993 Jan-Feb;13(1):37-45. [PubMed:8094898  (http://www.ncbi.nlm.nih.gov/pubmed/8094898)] 2. Doering W, Konig E, Sturm W: [Digitalis intoxication: specity and signicance of cardiac and extracardiac symptoms. part I: Patients with digitalis-induced arrhythmias (author's transl)]. Z Kardiol. 1977 Mar;66(3):121-8. [PubMed:857452  (http://www.ncbi.nlm.nih.gov/pubmed/857452)] 3. Kaplanski J, Weinhouse E, Topaz M, Genchik G: Verapamil and digoxin: interactions in the rat. Res Commun Chem Pathol Pharmacol. 1983 Dec;42(3):377-88. [PubMed:6665298  (http://www.ncbi.nlm.nih.gov/pubmed/6665298)] 4. Flanagan RJ, Jones AL: Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. [PubMed:15554746  (http://www.ncbi.nlm.nih.gov/pubmed/15554746)]

External Links Resource Link

Human Metabolome Database (HMDB) HMDB01917  (http://www.hmdb.ca/metabolites/HMDB01917)

KEGG Drug D00298  (http://www.genome.jp/dbget-bin/www_bget?drug:D00298)

KEGG Compound C06956  (http://www.genome.jp/dbget-bin/www_bget?cpd:C06956)

PubChem Compound 2724385  (http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2724385)

PubChem Substance 46508524  (http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508524)

BindingDB 46355  (http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=46355)

ChEBI 4551  (http://www.ebi.ac.uk/chebi/searchId.do?chebiId=4551)

ChEMBL CHEMBL1751  (http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1751)

Therapeutic Targets Database DAP000744  (http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000744)

PharmGKB PA449319  (http://www.pharmgkb.org/drug/PA449319)

HET DGX  (http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/DGX)

Drug Product Database 6731  (http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=6731&lang=eng)

RxList http://www.rxlist.com/cgi/generic/dig.htm  (http://www.rxlist.com/cgi/generic/dig.htm)

Drugs.com http://www.drugs.com/digoxin.html  (http://www.drugs.com/digoxin.html)

Wikipedia Digoxin  (http://en.wikipedia.org/wiki/Digoxin)

ATC Codes C01AA05 C01AA — Digitalis glycosides (/atc/C01AA) C01A — CARDIAC GLYCOSIDES (/atc/C01A) C01 — CARDIAC THERAPY (/atc/C01) C — CARDIOVASCULAR SYSTEM (/atc/C)

AHFS Codes 24:04.08 80:04.00

PDB Entries Not Available

FDA label Download (//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00390.pdf?1265922813) (563 KB)

MSDS Download (//s3-us-west-2.amazonaws.com/drugbank/msds/DB00390.pdf?1265922749) (74.6 KB)

Clinical Trials

https://www.drugbank.ca/drugs/DB00390 8/25 5/25/2017 Digoxin ­ DrugBank

Clinical Trials  Show 10 entries

Search

Phase Status  Purpose  Conditions  Count 

1 Active Not Other Healthy Volunteers 1 (/drugs/DB00390/clinical_trials? Recruiting (/indications/DBCOND0066957) conditions=DBCOND0066957&phase=1&purpose=other&status=active_not_recruiting)

1 Active Not Treatment Healthy Volunteers 1 (/drugs/DB00390/clinical_trials? Recruiting (/indications/DBCOND0066957) conditions=DBCOND0066957&phase=1&purpose=treatment&status=active_not_recruiting)

1 Active Not Treatment Hereditary Angioedema 1 (/drugs/DB00390/clinical_trials? Recruiting (/indications/DBCOND0032173) conditions=DBCOND0032173&phase=1&purpose=treatment&status=active_not_recruiting)

1 Active Not Treatment Inuenza in Humans 1 (/drugs/DB00390/clinical_trials? Recruiting (/indications/DBCOND0045403) conditions=DBCOND0045403&phase=1&purpose=treatment&status=active_not_recruiting)

1 Active Not Treatment Neoplasms 1 (/drugs/DB00390/clinical_trials? Recruiting (/indications/DBCOND0027948) conditions=DBCOND0027948&phase=1&purpose=treatment&status=active_not_recruiting)

1 Active Not Treatment CMET-dysregulated Advanced 1 (/drugs/DB00390/clinical_trials? Recruiting Solid Tumors conditions=DBCOND0079701&phase=1&purpose=treatment&status=active_not_recruiting) (/indications/DBCOND0079701)

1 Completed Not Drug-drug Interaction Study 1 (/drugs/DB00390/clinical_trials?conditions=DBCOND0072593&phase=1&status=completed) Available (/indications/DBCOND0072593)

1 Completed Not Healthy Volunteers 3 (/drugs/DB00390/clinical_trials?conditions=DBCOND0066957&phase=1&status=completed) Available (/indications/DBCOND0066957)

1 Completed Not Healthy Volunteers 1 (/drugs/DB00390/clinical_trials? Available (/indications/DBCOND0066957) conditions=DBCOND0066957%2CDBCOND0057367&phase=1&status=completed) / Pharmacokinetics of Digoxin (/indications/DBCOND0057367)

1 Completed Not Healthy Volunteers 1 (/drugs/DB00390/clinical_trials? Available (/indications/DBCOND0066957) conditions=DBCOND0066957%2CDBCOND0057367%2CDBCOND0053632&phase=1&status=completed) / Pharmacokinetics of Digoxin (/indications/DBCOND0057367) / Pharmacokinetics of Isavuconazole (/indications/DBCOND0053632)

Showing 1 to 10 of 67 entries

Previous 1 2 3 4 5 6 7 Next

Pharmacoeconomics

https://www.drugbank.ca/drugs/DB00390 9/25 5/25/2017 Digoxin ­ DrugBank

Manufacturers Glaxosmithkline llc Roxane laboratories inc Abraxis pharmaceutical products Baxter healthcare corp anesthesia and critical care Hospira inc Sandoz canada inc Wyeth ayerst laboratories Actavis totowa llc Caraco pharmaceutical laboratories ltd Impax laboratories inc Jerome stevens pharmaceuticals inc West ward pharmaceutical corp Smithkline beecham corp dba glaxosmithkline

Packagers Advanced Pharmaceutical Services Inc. Amerisource Health Services Corp. (http://www.amerisourcebergen.com) Apotheca Inc. A-S Medication Solutions LLC (http://orders.a-smeds.com) Baxter International Inc. (http://www.baxter.com) C.O. Truxton Inc. Caraco Pharmaceutical Labs (http://www.caraco.com) Cardinal Health (http://www.cardinal.com) Comprehensive Consultant Services Inc. Dept Health Central Pharmacy Direct Dispensing Inc. Dispensing Solutions (http://www.drxdispensing.com) Diversied Healthcare Services Inc. (http://www.dhscorp.com) Draxis Specialty Pharmaceuticals Inc. (http://www.draxispharma.com) DSM Corp. (http://www.dsm.com) Duramed (http://www.duramed.ca) General Injectables and Vaccines Inc. (http://www.giv.com) GlaxoSmithKline Inc. (http://www.gsk.com) Global Pharmaceuticals (http://www.globalphar.com) Heartland Repack Services LLC Hospira Inc. (http://www.hospira.com) Jerome Stevens Pharmaceuticals Inc. Kaiser Foundation Hospital Kraft Pharmaceutical Co. Inc. Lake Erie Medical and Surgical Supply Lannett Co. Inc. (http://www.lannett.com) Liberty Pharmaceuticals Major Pharmaceuticals (http://www.majorpharmaceuticals.com) Mckesson Corp. (http://www.mckesson.com) Murfreesboro Pharmaceutical Nursing Supply (http://www.unitdosesupply.com) Neuman Distributors Inc. Nucare Pharmaceuticals Inc. (http://www.nucarerx.com) https://www.drugbank.ca/drugs/DB00390 10/25 5/25/2017 Digoxin ­ DrugBank Palmetto Pharmaceuticals Inc. (http://www.palmettopharm.com) PCA LLC PD-Rx Pharmaceuticals Inc. (http://www.pdrx.com) Pharmedix (http://www.pharmedixrx.com) Physicians Total Care Inc. (http://www.physicianstotalcare.com) Prepackage Specialists Prepak Systems Inc. (http://www.prepaksys.com) Remedy Repack (http://www.remedyrepack.com) Resource Optimization and Innovation LLC Roxane Labs (http://www.roxane.com) Sandhills Packaging Inc. (http://www.sandhillspackaging.com) Sandoz (http://www.sandoz.ca) Savage Labs (http://www.savagelabs.com) Southwood Pharmaceuticals (http://www.southwoodhealthcare.com) Spectrum Pharmaceuticals (http://www.spectrumpharm.com) Talbert Medical Management Corp. UDL Laboratories (http://www.udllabs.com) Va Cmop Dallas Vangard Labs Inc. West-Ward Pharmaceuticals (http://www.west-ward.com)

Dosage forms Show 10 entries

Search

Form  Route  Strength 

Tablet Oral 0.0625 mg

Tablet Oral 0.125 mg

Tablet Oral 0.25 mg

Tablet Oral 125 ug/1

Tablet Oral 250 ug/1

Injection Intramuscular; Intravenous .25 mg/mL

Injection, solution Intramuscular; Intravenous; Parenteral 250 ug/mL

Solution Oral .05 mg/mL

Tablet Oral .125 mg/301

Tablet Oral .125 mg/1

Showing 1 to 10 of 26 entries

Previous 1 2 3 Next

https://www.drugbank.ca/drugs/DB00390 11/25 5/25/2017 Digoxin ­ DrugBank

Prices Show 10 entries

Search

Unit description  Cost  Unit 

Digibind 38 mg vial 727.91USD vial

Digifab 40 mg vial 615.6USD vial

Digoxin powder 450.28USD g

Digoxin 0.05 mg/ml Solution 60ml Bottle 36.99USD bottle

Lanoxin ped 0.1 mg/ml ampul 6.91USD ml

Digoxin Pediatric 0.05 mg/ml 6.79USD ml

Digoxin 0.25 mg/ml 2.91USD ml

Lanoxin 0.25 mg/ml ampul 1.44USD ml

Lanoxin 0.125 mg tablet 0.73USD tablet

Lanoxin 0.25 mg tablet 0.66USD tablet

Showing 1 to 10 of 25 entries

Previous 1 2 3 Next

 DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents Not Available

Properties

State Solid

Experimental Property Value Source Properties melting point (°C) 217-221 Stoll, A .and Kreis, W.; US.Patent 2,776,963; January 8,1957;assigned to Sandoz, AG, Switzerland.

water solubility 64.8 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992)

logP 1.26 SANGSTER (1993)

https://www.drugbank.ca/drugs/DB00390 12/25 5/25/2017 Digoxin ­ DrugBank

Predicted Property Value Source Properties Water Solubility 0.127 mg/mL ALOGPS (http://www.vcclab.org/lab/alogps/)

logP 1.04 ALOGPS (http://www.vcclab.org/lab/alogps/)

logP 2.37 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd)

logS -3.8 ALOGPS (http://www.vcclab.org/lab/alogps/)

pKa (Strongest Acidic) 7.15 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka)

pKa (Strongest Basic) -3 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka)

Physiological Charge 0 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka)

Hydrogen Acceptor Count 13 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond)

Hydrogen Donor Count 6 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond)

Polar Surface Area 203.06 Å2 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface)

Rotatable Bond Count 7 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis)

Refractivity 193.23 m3·mol-1 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity)

Polarizability 84.8 Å3 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization)

Number of Rings 8 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis)

Bioavailability 0 ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization)

Rule of Five Yes ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization)

Ghose Filter Yes ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization)

Veber's Rule Yes ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization)

MDDR-like Rule Yes ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization)

https://www.drugbank.ca/drugs/DB00390 13/25 5/25/2017 Digoxin ­ DrugBank

Predicted ADMET Property Value Probability features Human Intestinal Absorption + 0.941

Blood Brain Barrier - 0.7241

Caco-2 permeable - 0.8957

P-glycoprotein substrate Substrate 0.8586

P-glycoprotein inhibitor I Non-inhibitor 0.5325

P-glycoprotein inhibitor II Non-inhibitor 0.6209

Renal organic cation transporter Non-inhibitor 0.8621

CYP450 2C9 substrate Non-substrate 0.855

CYP450 2D6 substrate Non-substrate 0.9116

CYP450 3A4 substrate Substrate 0.7366

CYP450 1A2 substrate Non-inhibitor 0.9261

CYP450 2C9 inhibitor Non-inhibitor 0.9196

CYP450 2D6 inhibitor Non-inhibitor 0.9359

CYP450 2C19 inhibitor Non-inhibitor 0.9385

CYP450 3A4 inhibitor Non-inhibitor 0.9279

CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9279

Ames test Non AMES toxic 0.9233

Carcinogenicity Non-carcinogens 0.9668

Biodegradation Not ready biodegradable 0.9555

Rat acute toxicity 4.4721 LD50, mol/kg Not applicable

hERG inhibition (predictor I) Weak inhibitor 0.9818

hERG inhibition (predictor II) Inhibitor 0.8051

 ADMET data is predicted using admetSAR (http://lmmd.ecust.edu.cn:8000), a free tool for evaluating chemical ADMET properties. (23092397  (http://www.ncbi.nlm.nih.gov/pubmed/23092397))

Spectra

Mass Spec (NIST) Not Available

https://www.drugbank.ca/drugs/DB00390 14/25 5/25/2017 Digoxin ­ DrugBank

Spectra Spectrum Type Description Splash Key (http://splash.ehnlab.ucdavis.edu/)

Predicted LC-MS/MS Predicted LC-MS/MS Spectrum - 10V, Positive (/spectra/ms_ms/90039) Not Available

Predicted LC-MS/MS Predicted LC-MS/MS Spectrum - 20V, Positive (/spectra/ms_ms/90040) Not Available

Predicted LC-MS/MS Predicted LC-MS/MS Spectrum - 40V, Positive (/spectra/ms_ms/90041) Not Available

Predicted LC-MS/MS Predicted LC-MS/MS Spectrum - 10V, Negative (/spectra/ms_ms/153105) Not Available

Predicted LC-MS/MS Predicted LC-MS/MS Spectrum - 20V, Negative (/spectra/ms_ms/153106) Not Available

Predicted LC-MS/MS Predicted LC-MS/MS Spectrum - 40V, Negative (/spectra/ms_ms/153107) Not Available

Taxonomy

Description This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.

Kingdom Organic compounds  (http://classyre.wishartlab.com/tax_nodes/C0000000)

Super Class Lipids and lipid-like molecules  (http://classyre.wishartlab.com/tax_nodes/C0000012)

Class Steroids and steroid derivatives  (http://classyre.wishartlab.com/tax_nodes/C0000258)

Sub Class Steroid lactones  (http://classyre.wishartlab.com/tax_nodes/C0001125)

Direct Parent Cardenolide glycosides and derivatives  (http://classyre.wishartlab.com/tax_nodes/C0001559)

Alternative Parents Steroidal glycosides  (http://classyre.wishartlab.com/tax_nodes/C0001013) Oligosaccharides  (http://classyre.wishartlab.com/tax_nodes/C0000198) 12-hydroxysteroids  (http://classyre.wishartlab.com/tax_nodes/C0003241) 14-hydroxysteroids  (http://classyre.wishartlab.com/tax_nodes/C0004495) O-glycosyl compounds  (http://classyre.wishartlab.com/tax_nodes/C0002207) Oxanes  (http://classyre.wishartlab.com/tax_nodes/C0002012) Butenolides  (http://classyre.wishartlab.com/tax_nodes/C0002223) Tertiary alcohols  (http://classyre.wishartlab.com/tax_nodes/C0001670) Enoate esters  (http://classyre.wishartlab.com/tax_nodes/C0003626) Secondary alcohols  (http://classyre.wishartlab.com/tax_nodes/C0001661) Lactones  (http://classyre.wishartlab.com/tax_nodes/C0000050) Cyclic alcohols and derivatives  (http://classyre.wishartlab.com/tax_nodes/C0001292) Oxacyclic compounds  (http://classyre.wishartlab.com/tax_nodes/C0004140) Acetals  (http://classyre.wishartlab.com/tax_nodes/C0001656) Monocarboxylic acids and derivatives  (http://classyre.wishartlab.com/tax_nodes/C0001137) Organic oxides  (http://classyre.wishartlab.com/tax_nodes/C0003940) Carbonyl compounds  (http://classyre.wishartlab.com/tax_nodes/C0001831) Hydrocarbon derivatives  (http://classyre.wishartlab.com/tax_nodes/C0004150)

https://www.drugbank.ca/drugs/DB00390 15/25 5/25/2017 Digoxin ­ DrugBank

Substituents Cardanolide-glycoside Steroidal glycoside Oligosaccharide 12-hydroxysteroid 14-hydroxysteroid Hydroxysteroid Glycosyl compound O-glycosyl compound 2-furanone Oxane Cyclic alcohol Dihydrofuran Alpha,beta-unsaturated carboxylic ester Enoate ester Tertiary alcohol Lactone Carboxylic acid ester Secondary alcohol Organoheterocyclic compound Oxacycle Acetal Carboxylic acid derivative Monocarboxylic acid or derivatives Hydrocarbon derivative Alcohol Organic oxide Organic oxygen compound Carbonyl group Organooxygen compound Aliphatic heteropolycyclic compound

Molecular Aliphatic heteropolycyclic compounds Framework

External steroid saponin (CHEBI:4551  (http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4551)) Descriptors cardenolide glycoside (CHEBI:4551  (http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4551)) cardanolide (C06956  (http://www.genome.jp/dbget-bin/www_bget?cpd:C06956)) Cardanolides and derivatives (C06956  (http://www.genome.jp/dbget-bin/www_bget?cpd:C06956)) Cardanolide and derivatives (C06956  (http://www.genome.jp/dbget-bin/www_bget?cpd:C06956)) Cardiac glycosides (C06956  (http://www.genome.jp/dbget-bin/www_bget?cpd:C06956)) Terpenoids (C06956  (http://www.genome.jp/dbget-bin/www_bget?cpd:C06956))

Targets

1. Sodium/potassium-transporting ATPase subunit alpha-1 (/biodb/polypeptides/P05023)  Details (/biodb/polypeptides/P05023) https://www.drugbank.ca/drugs/DB00390 16/25 5/25/2017 Digoxin ­ DrugBank Kind Protein Organism Human Pharmacological action yes

General Function: Steroid hormone binding Specic Function: This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients. Gene Name: ATP1A1 Uniprot ID: P05023  (http://www.uniprot.org/uniprot/P05023) Molecular Weight: 112895.01 Da

References

1. Ravikumar A, Arun P, Devi KV, Augustine J, Kurup PA: Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders. Indian J Exp Biol. 2000 May;38(5):438-46. [PubMed:11272406  (http://www.ncbi.nlm.nih.gov/pubmed/11272406)] 2. Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248  (http://www.ncbi.nlm.nih.gov/pubmed/11309248)] 3. Ke YS, Liu ZF, Yang H, Yang T, Huang JS, Rui SB, Cheng GH, Wang YX: Effect of anti-digoxin antiserum on endoxin and membrane ATPase activity in hypoxia-reoxygenation induced myocardial injury. Acta Pharmacol Sin. 2000 Apr;21(4):345-7. [PubMed:11324464  (http://www.ncbi.nlm.nih.gov/pubmed/11324464)] 4. Kumar AR, Kurup PA: A hypothalamic digoxin mediated model for conscious and subliminal perception. J Neural Transm (Vienna). 2001;108(7):855-68. [PubMed:11515751  (http://www.ncbi.nlm.nih.gov/pubmed/11515751)] 5. Aizman O, Uhlen P, Lal M, Brismar H, Aperia A: Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13420-4. Epub 2001 Oct 30. [PubMed:11687608  (http://www.ncbi.nlm.nih.gov/pubmed/11687608)]

Enzymes

1. Cholesterol side-chain cleavage enzyme, mitochondrial (/biodb/polypeptides/P05108)  Details (/biodb/polypeptides/P05108)

Kind Protein Organism Human Pharmacological action unknown Actions inhibitor https://www.drugbank.ca/drugs/DB00390 17/25 5/25/2017 Digoxin ­ DrugBank General Function: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen Specic Function: Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone. Gene Name: CYP11A1 Uniprot ID: P05108  (http://www.uniprot.org/uniprot/P05108) Molecular Weight: 60101.87 Da

References

1. Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248  (http://www.ncbi.nlm.nih.gov/pubmed/11309248)] 2. Wang SW, Pu HF, Kan SF, Tseng CI, Lo MJ, Wang PS: Inhibitory effects of digoxin and digitoxin on corticosterone production in rat zona fasciculata-reticularis cells. Br J Pharmacol. 2004 Aug;142(7):1123-30. Epub 2004 Jul 12. [PubMed:15249423  (http://www.ncbi.nlm.nih.gov/pubmed/15249423)] 3. Lin H, Wang SW, Tsai SC, Chen JJ, Chiao YC, Lu CC, Huang WJ, Wang GJ, Chen CF, Wang PS: Inhibitory effect of digoxin on testosterone secretion through mechanisms involving decreases of cyclic AMP production and cytochrome P450scc activity in rat testicular interstitial cells. Br J Pharmacol. 1998 Dec;125(8):1635-40. [PubMed:9886754  (http://www.ncbi.nlm.nih.gov/pubmed/9886754)]

2. Cytochrome P450 3A4 (/biodb/polypeptides/P08684)  Details (/biodb/polypeptides/P08684)

Kind Protein Organism Human Pharmacological action unknown Actions substrate

General Function: Vitamin d3 25-hydroxylase activity Specic Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot... Gene Name: CYP3A4 Uniprot ID: P08684  (http://www.uniprot.org/uniprot/P08684) Molecular Weight: 57342.67 Da

References https://www.drugbank.ca/drugs/DB00390 18/25 5/25/2017 Digoxin ­ DrugBank

1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256  (http://www.ncbi.nlm.nih.gov/pubmed/19934256)]

Transporters

1. Multidrug resistance protein 1 (/biodb/polypeptides/P08183)  Details (/biodb/polypeptides/P08183)

Kind Protein Organism Human Pharmacological action unknown Actions substrate inhibitor inducer

General Function: Xenobiotic-transporting atpase activity Specic Function: Energy-dependent efux pump responsible for decreased drug accumulation in multidrug-resistant cells. Gene Name: ABCB1 Uniprot ID: P08183  (http://www.uniprot.org/uniprot/P08183) Molecular Weight: 141477.255 Da

References

https://www.drugbank.ca/drugs/DB00390 19/25 5/25/2017 Digoxin ­ DrugBank

1. Takara K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun. 2002 Mar 22;292(1):190-4. [PubMed:11890691  (http://www.ncbi.nlm.nih.gov/pubmed/11890691)] 2. Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun. 2003 Jun 20;306(1):116-20. [PubMed:12788075  (http://www.ncbi.nlm.nih.gov/pubmed/12788075)] 3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716- 25. [PubMed:12699389  (http://www.ncbi.nlm.nih.gov/pubmed/12699389)] 4. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9. [PubMed:10746169  (http://www.ncbi.nlm.nih.gov/pubmed/10746169)] 5. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identication studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899  (http://www.ncbi.nlm.nih.gov/pubmed/11181899)] 6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684  (http://www.ncbi.nlm.nih.gov/pubmed/11785684)] 7. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010  (http://www.ncbi.nlm.nih.gov/pubmed/12948010)] 8. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019  (http://www.ncbi.nlm.nih.gov/pubmed/12948019)] 9. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. [PubMed:14698039  (http://www.ncbi.nlm.nih.gov/pubmed/14698039)] 10. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1- dependent drug efux activity. Eur J Pharm Sci. 2004 Jan;21(1):69-75. [PubMed:14706813  (http://www.ncbi.nlm.nih.gov/pubmed/14706813)] 11. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5. [PubMed:1359120  (http://www.ncbi.nlm.nih.gov/pubmed/1359120)] 12. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation. 1999 Feb 2;99(4):552-7. [PubMed:9927403  (http://www.ncbi.nlm.nih.gov/pubmed/9927403)] 13. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. [PubMed:10227700  (http://www.ncbi.nlm.nih.gov/pubmed/10227700)] 14. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340  (http://www.ncbi.nlm.nih.gov/pubmed/15180340)] 15. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316  (http://www.ncbi.nlm.nih.gov/pubmed/15032316)] 16. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783  (http://www.ncbi.nlm.nih.gov/pubmed/19806783)] 17. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272  (http://www.ncbi.nlm.nih.gov/pubmed/19631272)]

2. Solute carrier organic anion transporter family member 4C1 (/biodb/polypeptides/Q6ZQN7)  Details (/biodb/polypeptides/Q6ZQN7)

Kind Protein Organism Human Pharmacological action unknown Actions inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity https://www.drugbank.ca/drugs/DB00390 20/25 5/25/2017 Digoxin ­ DrugBank Specic Function: Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the rst... Gene Name: SLCO4C1 Uniprot ID: Q6ZQN7  (http://www.uniprot.org/uniprot/Q6ZQN7) Molecular Weight: 78947.525 Da

References

1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604  (http://www.ncbi.nlm.nih.gov/pubmed/14993604)]

3. Solute carrier family 22 member 8 (/biodb/polypeptides/Q8TCC7)  Details (/biodb/polypeptides/Q8TCC7)

Kind Protein Organism Human Pharmacological action unknown Actions inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity Specic Function: Plays an important role in the excretion/detoxication of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA). Gene Name: SLC22A8 Uniprot ID: Q8TCC7  (http://www.uniprot.org/uniprot/Q8TCC7) Molecular Weight: 59855.585 Da

References

https://www.drugbank.ca/drugs/DB00390 21/25 5/25/2017 Digoxin ­ DrugBank

1. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecic organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140  (http://www.ncbi.nlm.nih.gov/pubmed/10224140)]

4. Solute carrier organic anion transporter family member 2B1 (/biodb/polypeptides/O94956)  Details (/biodb/polypeptides/O94956)

Kind Protein Organism Human Pharmacological action unknown Actions substrate

General Function: Sodium-independent organic anion transmembrane transporter activity Specic Function: Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost. Gene Name: SLCO2B1 Uniprot ID: O94956  (http://www.uniprot.org/uniprot/O94956) Molecular Weight: 76709.98 Da

References

1. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T: Molecular identication of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8. [PubMed:10973807  (http://www.ncbi.nlm.nih.gov/pubmed/10973807)]

5. Bile salt export pump (/biodb/polypeptides/O95342)  Details (/biodb/polypeptides/O95342)

Kind Protein Organism Human Pharmacological action unknown Actions substrate https://www.drugbank.ca/drugs/DB00390 22/25 5/25/2017 Digoxin ­ DrugBank General Function: Transporter activity Specic Function: Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes. Gene Name: ABCB11 Uniprot ID: O95342  (http://www.uniprot.org/uniprot/O95342) Molecular Weight: 146405.83 Da

References

1. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P- glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675  (http://www.ncbi.nlm.nih.gov/pubmed/10617675)]

6. Solute carrier organic anion transporter family member 1A2 (/biodb/polypeptides/P46721)  Details (/biodb/polypeptides/P46721)

Kind Protein Organism Human Pharmacological action unknown Actions substrate

General Function: Sodium-independent organic anion transmembrane transporter activity Specic Function: Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin. Gene Name: SLCO1A2 Uniprot ID: P46721  (http://www.uniprot.org/uniprot/P46721) Molecular Weight: 74144.105 Da

References

https://www.drugbank.ca/drugs/DB00390 23/25 5/25/2017 Digoxin ­ DrugBank

1. Hagenbuch B, Adler ID, Schmid TE: Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20. [PubMed:10600646  (http://www.ncbi.nlm.nih.gov/pubmed/10600646)] 2. Noe B, Hagenbuch B, Stieger B, Meier PJ: Isolation of a multispecic organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10346-50. [PubMed:9294213  (http://www.ncbi.nlm.nih.gov/pubmed/9294213)]

7. Organic solute transporter subunit alpha (/biodb/polypeptides/Q86UW1)  Details (/biodb/polypeptides/Q86UW1)

Kind Protein Organism Human Pharmacological action unknown Actions substrate

General Function: Transporter activity Specic Function: Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efciently transports the major species of bile acids. Gene Name: SLC51A Uniprot ID: Q86UW1  (http://www.uniprot.org/uniprot/Q86UW1) Molecular Weight: 37734.575 Da

References

1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha- OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432  (http://www.ncbi.nlm.nih.gov/pubmed/12719432)]

8. Organic solute transporter subunit beta (/biodb/polypeptides/Q86UW2)  Details (/biodb/polypeptides/Q86UW2)

Kind Protein Organism Human Pharmacological action unknown https://www.drugbank.ca/drugs/DB00390 24/25 5/25/2017 Digoxin ­ DrugBank Actions substrate

General Function: Transporter activity Specic Function: Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efciently transports the major species of bile acids. Modulates SLC51A glycosylation, membrane trafcking and stability activities. Gene Name: SLC51B Uniprot ID: Q86UW2  (http://www.uniprot.org/uniprot/Q86UW2) Molecular Weight: 14346.195 Da

References

1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha- OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432  (http://www.ncbi.nlm.nih.gov/pubmed/12719432)]

9. Solute carrier organic anion transporter family member 4A1 (/biodb/polypeptides/Q96BD0)  Details (/biodb/polypeptides/Q96BD0)

Kind Protein Organism Human Pharmacological action unknown Actions substrate

General Function: Thyroid hormone transmembrane transporter activity Specic Function: Mediates the Na(+)-independent transport of organic anions such as the thyroid hormones T3 (triiodo-L-thyronine), T4 (thyroxine) and rT3, and of estrone-3-sulfate and taurocholate. Gene Name: SLCO4A1 Uniprot ID: Q96BD0  (http://www.uniprot.org/uniprot/Q96BD0) Molecular Weight: 77192.505 Da

References https://www.drugbank.ca/drugs/DB00390 25/25